Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Methoxyethanol SCHEMBL1317307 | 0.96 | TSHR (0.47) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| 2-Methoxyethanol SCHEMBL310 | 0.96 | — | — | |
| 2-Methoxyethanol SCHEMBL5050349 | 0.92 | — | — | |
| 2-Methoxyethanol SCHEMBL3810075 | 0.92 | — | — | |
| 2-Methoxyethanol SCHEMBL7944654 | 0.92 | TSHR (0.44) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| 2-Methoxyethanol SCHEMBL7703885 | 0.92 | TSHR (0.44) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| 2-Methoxyethanol SCHEMBL8506499 | 0.92 | — | — | |
| 2-Methoxyethanol SCHEMBL3886889 | 0.92 | — | — | |
| 2-Methoxyethanol SCHEMBL21403186 | 0.92 | — | — | |
| 2-Methoxyethanol SCHEMBL4455759 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116265463-A | Crystal form of aldose reductase inhibitor, and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-116265463-A | Crystal form of aldose reductase inhibitor, and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-10407355-B2 | Lignin processing | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2019-09-10 | — | — | US | disclosed |
| EP-3183226-A1 | DEPOLYMERISATION OF OXIDISED LIGNIN | University Court of The University of St Andrews (GB) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016027091-A1 | DEPOLYMERISATION OF OXIDISED LIGNIN | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2016-02-25 | — | — | WO | disclosed |
| EP-2328861-A2 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE | Synthon BV (NL) | 2011-06-08 | — | — | EP | disclosed |
| WO-2011012140-A2 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE | SYNTHON BV (NL) | 2011-02-03 | — | — | WO | disclosed |
| EP-1029867-B1 | Process for the preparation of organic azides | AKZO NOBEL NV (NL) | 2004-04-28 | — | — | EP | disclosed |
| EP-0514917-B1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1996-12-27 | — | — | EP | disclosed |
| US-5391737-A | Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one | EGIS GYOGYSZERGYAR (HU) | 1995-02-21 | — | — | US | disclosed |
| EP-0514917-A1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGIS GYOGYSZERGYAR (HU) | 1992-11-25 | — | — | EP | disclosed |
| EP-0240175-B1 | INOSOSE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4824943-A | Inosose derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| US-4803303-A | VALIOLAMINE COMPOUNDS FOR HYPERGLYCEMIA TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| EP-0240175-A1 | Inosose derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407355-B2 | Lignin processing | NOX4, SOD1, LPO | TSHR 4710/4885MAPK1 2126/4885ALDH1A1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.